TARA · Protara Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $42.63M | $31.70M | $24.99M | $16.81M | $21.09M | $11.98M |
| SG&A | $21.92M | $17.45M | $18.62M | $20.74M | $26.40M | $22.46M |
| Total Operating Expenses | $64.55M | $49.15M | $43.61M | $67.06M | $47.49M | $34.44M |
| D&A | $362.0K | $332.0K | $341.0K | $248.0K | $117.0K | $103.0K |
| Operating Income | ($64.55M) | ($49.15M) | ($43.61M) | ($67.06M) | ($47.49M) | ($34.44M) |
| Interest Expense | - | - | - | - | $0 | $34.0K |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($57.44M) | ($44.60M) | ($40.42M) | ($65.95M) | ($47.25M) | ($33.98M) |
| EPS - Basic | ($1.34) | ($2.17) | ($3.57) | ($4.21) | - | - |
| EPS - Diluted | ($1.34) | ($2.17) | ($3.57) | ($5.86) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.66M | $162.80M | $39.59M | $24.13M | $35.72M | $168.60M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.47M | $4.43M | $2.43M | $1.59M | $954.0K | $914.0K |
| Current Assets | $159.50M | $172.16M | $68.70M | $86.15M | $93.11M | $169.44M |
| Total Assets | $209.47M | $181.45M | $78.95M | $113.29M | $172.60M | $203.16M |
| Current Liabilities | $10.94M | $10.96M | $6.15M | $5.74M | $4.30M | $2.92M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $13.06M | $14.32M | $10.63M | $11.21M | $10.68M | $3.91M |
| Stockholders' Equity | $196.41M | $167.13M | $68.32M | $102.08M | $161.91M | $199.24M |
| Retained Earnings | ($302.42M) | ($244.98M) | ($200.38M) | ($159.96M) | ($94.01M) | ($46.76M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($56.37M) | ($35.81M) | ($37.56M) | ($26.46M) | ($34.50M) | ($23.41M) |
| Investing Cash Flow | ($139.49M) | $19.16M | $53.11M | $14.95M | ($98.19M) | $2.83M |
| Financing Cash Flow | $82.72M | $139.87M | ($91.0K) | ($90.0K) | ($228.0K) | $189.40M |
| CapEx | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K |
| Free Cash Flow | ($56.46M) | ($35.87M) | ($37.60M) | ($26.58M) | ($35.10M) | ($24.29M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.98 | 0.80 | 0.93 | 0.40 | 0.74 | 0.71 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -27.4% | -24.6% | -51.2% | -58.2% | -27.4% | -16.7% |
| Return on equity | -29.2% | -26.7% | -59.2% | -64.6% | -29.2% | -17.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 14.58 | 15.71 | 11.17 | 15.01 | 21.66 | 58.13 |
| Quick ratio | 14.58 | 15.71 | 11.17 | 15.01 | 21.66 | 58.13 |
| Cash ratio | 4.54 | 14.85 | 6.44 | 4.20 | 8.31 | 57.84 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -1013.1x |
| Equity multiplier | 1.07 | 1.09 | 1.16 | 1.11 | 1.07 | 1.02 |
| Liabilities / Assets | 0.06 | 0.08 | 0.13 | 0.10 | 0.06 | 0.02 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.2x | 0.7x | 0.3x | 0.3x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -31.3% | -12.7% | 35.0% | -41.2% | -37.9% | -125.8% |
| Net income growth (YoY) | -28.8% | -10.3% | 38.7% | -39.6% | -39.1% | -126.6% |
| EPS growth (YoY) | 38.2% | 39.2% | 39.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -57.4% | 4.6% | -41.5% | 24.3% | -44.5% | -55.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 17.5% | 144.6% | -33.1% | -37.0% | -18.7% | 3017.1% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Protara Therapeutics against the 5 most active filers in the same SIC group.